L-cystine crystal

L-cystine crystals are the primary pathological drivers of cystinuria, a rare genetic disorder caused by mutations in the SLC3A1 or SLC7A9 genes, which encode the renal dibasic amino acid transporter (Source: StatPearls, 2023). When these transporters fail, cystine reaches high concentrations in the urine, where its poor solubility leads to the formation of hexagonal crystals (Source: PubChem, 2024). These crystals aggregate into hard, branched stones that are notoriously resistant to conventional treatments like extracorporeal shock wave lithotripsy (Source: NIDDK, 2020). Therapeutic management focuses on increasing cystine solubility through urinary alkalinization and the administration of thiol-based drugs like tiopronin, which chemically modify cystine into more soluble forms (Source: NIH, 2022). Recent pharmacological research has also identified crystal growth inhibitors, such as L-cystine dimethyl ester, that bind to specific faces of the L-cystine crystal to prevent its expansion, representing a direct targeting of the crystalline structure itself (Source: Rimer et al., Science, 2010). This approach aims to prevent the transition from microscopic crystals to macroscopic, obstructive stones.

Other names

Cystine stoneCystine calculusHexagonal cystine crystalDicysteine crystal

Thiol-disulfide exchange to form soluble mixed disulfides and stereospecific crystal growth inhibition.